|
|
|
Volumn 10, Issue 5, 2004, Pages
|
|
Value for money in disease management of benign prostatic hyperplasia.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;
GENERIC DRUG;
SULFONAMIDE;
TAMSULOSIN;
COST BENEFIT ANALYSIS;
ECONOMICS;
HUMAN;
MALE;
NOTE;
PROSTATE HYPERTROPHY;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
DIABETES MELLITUS;
EDITORIAL;
HEALTH INSURANCE;
HEPATITIS C;
PRACTICE GUIDELINE;
PUBLIC HOSPITAL;
STANDARD;
TREATMENT OUTCOME;
UNITED STATES;
ADRENERGIC ALPHA-ANTAGONISTS;
COST-BENEFIT ANALYSIS;
DRUGS, GENERIC;
HUMANS;
MALE;
PROSTATIC HYPERPLASIA;
SULFONAMIDES;
DIABETES MELLITUS;
HEPATITIS C;
HOSPITALS, VETERANS;
MANAGED CARE PROGRAMS;
PRACTICE GUIDELINES;
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;
TREATMENT OUTCOME;
UNITED STATES;
|
|
EID: 6044237856
PISSN: 10834087
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (1)
|
|
References (28)
|
